<DOC>
	<DOC>NCT00699517</DOC>
	<brief_summary>The primary objective of the study is to compare the progression-free survival (PFS) in the 2 treatment arms The secondary objectives of the study are : - To compare the overall survival in the 2 treatment arms - To compare the objective response rate in the 2 treatment arms - To assess the safety profile of AVE8062 (in combination with the background cisplatin therapy) - To assess the pharmacokinetics of AVE8062 and its main metabolite, RPR258063, using a population approach, in all patients enrolled in selected centers.</brief_summary>
	<brief_title>A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Inclusion criteria: Histologically proven soft tissue sarcoma Unresectable locoregional recurrent or metastatic soft tissue sarcoma Failure of a previous anthracyclinebased regimen administered recommended dose and of prior ifosfamide therapy Exclusion criteria: Less than 3 weeks elapsed from prior treatment with radiotherapy, surgery, or chemotherapy to the time of randomization Brain metastases and carcinomatous leptomeningitis Uncontrolled hypertension Known platinum hypersensitivity The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>tubulin modulator</keyword>
	<keyword>endothelium</keyword>
	<keyword>combretastatin</keyword>
	<keyword>cisplatin</keyword>
</DOC>